Abstracts tagged "Pediatric rheumatology"

Abstract Number: 1621 • ACR Convergence 2023
Maxillofacial MRI Augments Detection of Non-CNS Abnormalities in Pediatric Craniofacial Scleroderma
Daniel Glaser¹, Amy Metry², Elena DeRosas², Subramanian Subramanian² and Kathryn Torok³, ¹Yale University School of Medicine, New Haven, CT, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Craniofacial scleroderma is a rare subtype of linear scleroderma affecting the head and neck. Up to 40% of patients experience extracutaneous manifestations (ECMs), but…
Abstract Number: 2040 • ACR Convergence 2023
Distinguishing Multisystem Inflammatory Syndrome in Children from Typhus Using Artificial Intelligence: MISC vs. Endemic Typhus (AI-MET)
Angela Chun¹, Abraham Bautista-Castillo², Isabella Osuna¹, Kristiana Nasto¹, Flor Munoz³, Gordon Schutze¹, Sridevi Devaraj¹, Eyal Muscal⁴, Marietta De Guzman⁵, Kristen Sexson Tejtel¹, Ioannis Kakadiaris² and Tiphanie Vogel¹, ¹Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ²Computational Biomedicine Lab University of Houston, Houston, TX, ³Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, ⁵Baylor College of Medicine, Houston, TX
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) following SARS-CoV2infection is a recognized mimic of other inflammatory disorders, including Kawasaki Disease and macrophage activation syndrome. However,…
Abstract Number: 2062 • ACR Convergence 2023
A Mental Health Workshop for Pediatric Rheumatology Fellows
Caitlan Pinotti¹, Alison Manning², Suzanne Edison³ and Rebecca Sadun¹, ¹Duke University, Durham, NC, ²Lifespan, East Providence, RI, ³Cure JM Foundation, Seattle, WA
Background/Purpose: Many children with a rheumatic disease have concurrent mental and behavioral health challenges, but only ~40% of these symptoms are brought to medical attention.…
Abstract Number: 0028 • ACR Convergence 2023
Adenosine Deaminase 2 Is Expressed as a Short Isoform Lacking Deaminase Activity in the Endothelium: Implications for DADA2 Vasculitis
Andrew Porter¹, Robert Maughan¹, Charis Pericleous¹, Lida Kabir¹, Richard Stratton², Dorian Haskard¹, Pui Lee³, Taryn Youngstein¹ and Justin Mason¹, ¹National Heart & Lung Institute, Imperial College London, London, United Kingdom, ²University College London, London, United Kingdom, ³Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive condition caused by biallelic variants in the Adenosine deaminase 2 (ADA2) gene. Clinical manifestations…
Abstract Number: 0360 • ACR Convergence 2023
Increasing the Etanercept Dose in Juvenile Idiopathic Arthritis Patients: Does It Help Reaching the Treatment Target? A Post-hoc Analysis of the Best4Kids Randomised Clinical Trial
Bastiaan van Dijk¹, Sytske Anne Bergstra¹, Merlijn van den Berg², Dieneke Schonenberg-Meinema², Lisette van Suijlekom-Smit², Marion van Rossum³, Yvonne Koopman⁴, Rebecca Ten Cate¹, CF Allaart¹, Danielle Brinkman¹ and Petra Hissink Muller¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Amsterdam Rheumatology and Immunology Center | Reade, Amstelveen, Netherlands, ⁴HagaZiekenhuis Juliana Children's Hospital, The Hague, Netherlands
Background/Purpose: The relation between etanercept dose and clinical outcomes of juvenile idiopathic arthritis (JIA) is unclear. Most studies only evaluated doses up to 0.8 mg/kg/week…
Abstract Number: 0760 • ACR Convergence 2023
Treatment Patterns and Outcomes in Patients with Macrophage Activation Syndrome Secondary to Still’s Disease Treated with Emapalumab: The REAL-HLH Study
Carl Allen¹, Shanmuganathan Chandrakasan², Michael Jordan³, Jennifer Leiding⁴, Abiola Oladapo⁵, Priti Pednekar⁶, Kelly Walkovich⁷ and John Yee⁵, ¹Baylor College of Medicine, Houston, TX, ²Emory University School of Medicine, Atlanta, GA, ³Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Division of Allergy and Immunology, Department of Pediatrics, Johns Hopkins University; bluebird bio, Cambridge, MA, ⁵Sobi, Inc., Waltham, MA, ⁶PRECISIONheor, Bethesda, MD, ⁷Division of Pediatric Hematology Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI
Background/Purpose: Macrophage activating syndrome (MAS) is a rare, potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD). MAS (a form…
Abstract Number: 1224 • ACR Convergence 2023
Mental Health Screening Follow-Up in the Childhood-Onset Systemic Lupus Clinic
Audrea Chen¹, Tala El Tal², Asha Jeyanathan¹, Holly Convery¹, Stephanie Wong¹, Linda Hiraki¹, Deborah Levy¹ and Andrea Knight¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada
Background/Purpose: Common barriers to conducting mental health (MH) screening in pediatric clinics include provider uncertainty with follow-up after screening, and concern with increasing burden of…
Abstract Number: 1241 • ACR Convergence 2023
Adverse Childhood Experiences in a Paediatric Systemic Lupus Erythematosus Cohort
Stephanie Fevrier¹, Olivia Hendrikx¹, Ashley Danguecan¹, Asha Jeyanathan¹, Lawrence Ng¹, Ibrahim Mohamed², Paris Moaf¹, Sondos Ayyash¹, Chelsea DeCoste³, Deborah Levy¹, Linda Hiraki¹ and Andrea Knight¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Brampton, ON, Canada, ³IWK Health Centre, Halifax, NS, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multiorgan autoimmune disease in which 20% of cases are diagnosed in childhood. Adverse childhood experiences (ACEs) are…
Abstract Number: 1622 • ACR Convergence 2023
Myositis-associated Autoantibodies in Juvenile Myositis Are Associated with Severe Disease Features and Mortality
Matthew Sherman¹, Payam Noroozi Farhad², Katherine Pak³, Iago Pinal-Fernandez³, Kakali Sarkar², Megan Neely⁴, Ira Targoff⁵, Frederick Miller⁶, Andrew Mammen⁷ and Lisa Rider⁸, ¹NIAMS/NIH, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, ⁵Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶NIH, NIEHS, Chapel Hill, NC, ⁷NIH, Bethesda, MD, ⁸NIEHS, NIH, Bethesda, MD
Background/Purpose: Myositis-associated autoantibodies (MAAs), such as anti-Ro52 autoantibodies (Abs), have been found to be associated with interstitial lung disease (ILD) and worse prognosis in the…
Abstract Number: 2041 • ACR Convergence 2023
An Analysis of Recurrent Parotitis Patients Referred to Rheumatology Clinic
Yiressy Pina¹, Elton Lambert², Maria Pereira² and Marietta De Guzman², ¹Baylor College of Medicine, Richmond, TX, ²Baylor College of Medicine, Houston, TX
Background/Purpose: Juvenile recurrent parotitis (JRP) is characterized by non-obstructive, non-suppurative inflammation of the parotid glands of unknown etiology. The onset of symptoms occurs typically between…
Abstract Number: 2086 • ACR Convergence 2023
From Fellow to Fellowship Director: Gender Equity in Pediatric Rheumatology Pipeline
Bessie Roca loor¹, Maya Pandit², Tracey Wright³ and Mill Etienne⁴, ¹New York Medical College, Yonkers, NY, ²Columbia University, New York, NY, ³UT Southwestern, Dallas, TX, ⁴New York Medical College, Valhalla, NY
Background/Purpose: As the demand for pediatric rheumatologists rise across the United States with a projected demand of almost 100% more pediatric rheumatologists needed by 2030…
Abstract Number: 027 • 2023 Pediatric Rheumatology Symposium
Identifying and Understanding JDM in Africa: A Survey of Rheumatology Care Providers from Africa
Jessica Perfetto¹, Laura Lewandowski², Dawn Wahezi¹, Christiaan Scott³ and Angela Migowa⁴, ¹Children's Hospital at Montefiore, New York, NY, ²NIAMS, NIH, Bethesda, MD, ³Red Cross War Memorial Children's Hospital, ⁴Aga Khan University, Nairobi, Kenya
Background/Purpose: There is a paucity of data on pediatric rheumatic disease (PRD) in low and middle-income countries (LMIC), creating a false perception of low prevalence…
Abstract Number: 059 • 2023 Pediatric Rheumatology Symposium
Update of Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort
Esraa Eloseily¹, Min-Lee Chang², Mary Ellen Riordan³, allan Russell⁴, Marc Natter², Yukiko Kimura⁵ and Grant Schulert¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Boston Children's Hospital, Boston, MA, ³Hackensack Meridian Health/ Joseph M. Sanzari Children's Hospital, Hackensack, NJ, ⁴Duke Clinical Research Institute, Durham, NC, ⁵Hackensack Meridian School of Medicine, Hackensack, NJ
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life-threatening clinical problem. Despite recent advances, there remain key unanswered questions…
Abstract Number: 102 • 2023 Pediatric Rheumatology Symposium
Preliminary Results from a Survey of Psychological Resilience Among JIA Patients
Daniella Schocken and Tracy Ting, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Psychological resilience – an individuals capacity to adapt in the face of stressors and recover after adverse events – has been linked to a…
Abstract Number: 031 • 2023 Pediatric Rheumatology Symposium
Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants
Greta Mastrangelo¹, Ellen Go², Paul Tsoukas², Hua Lu³, Amy Xu², Arthur Hoi Hin Cheng² and Rae Yeung⁴, ¹The Hospital of Sick Children,Department of Paediatrics, University of Toronto, Division of Rheumatology, Toronto, ON, Canada, ²The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious complication associated with COVID-19, presenting as a hyperinflammatory disorder characterized by fever and multiorgan dysfunction.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].